anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Hepatocellular carcinoma (HCC) is a malignant tumor with extremely high mortality. The tumor microenvironment is the "soil" of its occurrence and development, and the inflammatory microenvironment is an important part of the "soil". Bile acid is closely related to the occurrence of HCC. Bile acid metabolism disorder is not only directly involved in the occurrence and development of HCC but also affects the inflammatory microenvironment of HCC. Yinchenhao decoction, a traditional Chinese medicine formula, can regulate bile acid metabolism and may affect the inflammatory microenvironment of HCC. To determine the effect of Yinchenhao decoction on bile acid metabolism in mice with HCC and to explore the possible mechanism by which Yinchenhao decoction improves the inflammatory microenvironment of HCC by regulating bile acid metabolism, we established mice model of orthotopic transplantation of hepatocellular carcinoma. These mice were treated with three doses of Yinchenhao decoction, then liver samples were collected and tested. Yinchenhao decoction can regulate the disorder of bile acid metabolism in liver cancer mice. Besides, it can improve inflammatory reactions, reduce hepatocyte degeneration and necrosis, and even reduce liver weight and the liver index. Taurochenodeoxycholic acid, hyodeoxycholic acid, and taurohyodeoxycholic acid are important molecules in the regulation of the liver inflammatory microenvironment, laying a foundation for the regulation of the liver tumor inflammatory microenvironment based on bile acids. Yinchenhao decoction may improve the inflammatory microenvironment of mice with HCC by ameliorating hepatic bile acid metabolism.
The human truncated recombinant soluble TRAIL-180 protein is one TRAIL protein segment including amino acids 102-281.  In the first stage of protein structure, there are threonine in N terminal, glycine in C terminal, 11 arginines, 6 histidines, 11 lysined and 1 cysteine, isoelectric point PI=9.14, and it is one alkali protein.  In its second stage structure, the protein includes two beta layer parallel but opposite in direction.  The protein has cDNA sequence comprising 540 nucleotides and encodes 180 amino acids.  The protein can induce the tumor cells to die obviously kill and/or inhibit tumor cells in animal body.  Compared with TRAIL95-282 segment used internationally, the human truncated recombinant soluble TRAIL-180 protein of the present invention has the features of small molecular weight and high activity and has wide application foreground in preparing tumor treating medicine.
INTRODUCTION: Our aim was to describe a monocentric cohort of young adult patients with juvenile idiopathic arthritis (JIA), assessing the risk of relapse after transition to adult care.
METHODS: We conducted a retrospective study and collected clinical, serological, and demographic data of young adult patients (18-30 years old) referred to the Transition Clinic of a single Italian centre between January 2020 and March 2023. Patients with systemic-onset JIA were excluded. Primary outcome was disease relapse, defined by Wallace criteria. Risk factors were analysed by Cox proportional hazards regression.
RESULTS: Fifty patients with age 18-30 years old were enrolled in the study and followed for a median 30 months. The median disease duration at transition was 15 years. Twenty (40%) patients were on conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and 38 (76%) were on biological DMARDs through adulthood. Twenty-three patients relapsed after transitioning to adult care for a median 9-month follow-up (IQR 0-46.5). Most relapses involved the knees (69.6%). The univariate analysis identified monoarthritis (HR 4.67, CI 1.069-20.41, p value = 0.041) as the main risk factor for relapse within the first 36 months of follow-up. Early onset, ANA positivity, past and ongoing treatment with csDMARDs or bDMARDs, therapeutic withdrawal, and disease activity within 12 months before transition did not significantly influence the risk of relapse.
CONCLUSION: In JIA patients, the risk of relapse after transitioning to adult care remains high, irrespective of disease subtype and treatment. The main risk factor for the early occurrence of articular activity is monoarticular involvement.
Bilateral P6 point acupuncture will be performed intra-operatively by the PI, who has UC Davis Medical Center privilege for this specific acupuncture, while the patient is under anesthesia. Patient will be sent home with an acupressure band, which is to remain on for 24 hours post operatively.
ETHNOPHARMACOLOGICAL RELEVANCE: Fufangxiaopi Formula (FF) is a modified form of Sishen Wan, traditionally used for treating diarrhea. The application of FF for treating ulcerative colitis (UC) has achieved desirable outcomes in clinical settings. However, the underlying mechanism of the effect of FF on UC is yet to be determined.
AIM OF STUDY: This study aimed to evaluate the protective effect and underlying mechanism of FF on mice with dextran sodium sulfate (DSS)-induced colitis.
MATERIALS AND METHODS: In vivo, the efficacy of FF on the symptoms associated with DSS-induced colitis in mice was clarified by observing the body weight change, colon length, DAI score, and H&E staining. The release of inflammatory mediators in mouse colon tissues was detected by ELISA and MPO, and the contents of TLR4/NF-κB signaling pathway and MAPK signaling pathway-related proteins, as well as intestinal barrier-related proteins, were detected in mouse colon tissues by western blot method. Changes in the content of barrier proteins in mouse colon tissues were detected by immunofluorescence. 16S rRNA sequencing and FMT were performed to clarify the effects of FF on intestinal flora. In vitro, the effect of FF-containing serum on LPS-induced inflammatory mediator release from RAW264.7 cells were detected by qRT-PCR. The contents of TLR4/NF The effects of FF-containing serum on B signaling pathway and MAPK signaling pathway related proteins in RAW264.7 cells and intestinal barrier related proteins in Caco-2 cells were detected by western blot. The effects of FF-containing serum on LPS-induced nuclear translocation of p65 protein in RAW264.7 cells and barrier-associated protein in Caco-2 cells were detected by immunofluorescence.
RESULTS: In vivo studies showed that FF could significantly alleviate the symptoms of UC, including reducing colon length, weight loss, clinical score, and colon tissue injury in mice. FF could significantly reduce the secretion of proinflammatory cytokines by suppressing the activation of the TLR4/NF-κB and MAPK signaling pathways. Moreover, FF could protect the integrity of intestinal barriers by significantly increasing claudin-3, occludin, and ZO-1 expression levels. 16S rRNA sequencing and FMT elucidate that FF can alleviate symptoms associated with colitis in mice by interfering with intestinal flora. In vitro studies showed that FF drug-containing serum could significantly inhibit proinflammatory responses and attenuate the secretion of iNOS, IL-1β, TNF-α, IL-6, and COX-2 by suppressing the activation of TLR4/NF-κB and MAPK signaling pathways in RAW264.7 cells. Furthermore, FF could protect the Caco-2 cell epithelial barrier.
CONCLUSION: FF could alleviate DSS-induced colitis in mice by maintaining the intestinal barrier, inhibiting the activation of TLR4/NF-κB and MAPK signaling pathways, reducing the release of proinflammatory factors, and regulating intestinal microecology.
NEW MATERIAL:A 4-hydroxydibenzoylmethane derivative of formula I (R is 2-26C linear or alicyclic hydrocarbon group or 2-26C alkoxy). EXAMPLE:4-Hydroxy-4'-tert-butyldibenzoylmethane. USE:Useful as an UV light absorbent, especially as a long wavelength UV light absorbent for cosmetics. The compound of formula I effectively absorbs the light in the wavelength region of 320-400nm, has excellent optical stability and exhibits good compatibility with various basic materials for cosmetics, organic solvents, etc. PREPARATION:For example, a substituted acetophenone of formula II whose phenolic hydroxide group is protected with a suitable protecting group such as pyranyl ether group is subjected to a Claisen condensation with a substituted aromatic ester of formula III. The protecting group of the phenolic hydroxyl group is removed from the resultant compound of formula IV by a method such as a hydrolysis reaction using an acid catalyst to provide the compound of formula I.
PURPOSE: A functional cosmetic composition for skin regeneration is provided to enable easy transdermal absorption and skin care, to enhance skin regeneration effect with low cytotoxicity, and to prevent aging. CONSTITUTION: A functional cosmetic composition contains 5-aminolevulinic acid or a cosmetically acceptable salt thereof as an active ingredient. The salt is a compound denoted by chemical formula II: R_2·NH_2-CH_2-CO-CH_2-CH_2-CO-O-R_1. 5-aminolevulinic acid or the salt is contained in 5-10 parts by weight based on 100 parts by weight of a makeup base. The makeup base is selected from the group consisting of stearyl alcohol, polyethylene glycol, or purified water. A functional cosmetic composition for single use for skin regeneration contains 50-75 mg of 5-aminolevulinic acid or the salt thereof.
BACKGROUND: Rare diseases in Europe are defined as diseases with a prevalence of less than 5 per 10,000 people. Despite their individual rarity, the total number of rare diseases is considerable. Rare diseases are often chronic and complex, affecting physical, mental, and neurological health. People with rare diseases face challenges such as delayed diagnosis, limited medical support, and financial burden. Caregivers, usually family members, bear significant physical and emotional burdens. Understanding the experiences of patients with rare disease and their caregivers is critical to effective care, but this is still underresearched. Better support and understanding of the challenges faced by both patients and caregivers is clearly needed. Our study will explore the experiences and needs of people with rare diseases and caregivers of people with rare diseases in relation to accessing health services.
OBJECTIVE: This study aims to explore the experiences of patients with rare disease and their caregivers with Slovenian health care providers and to create a theoretical model of needs and experiences.
METHODS: This is a qualitative thematic analysis study, using the codebook approach. The study will conduct semi-open-ended interviews to understand the experiences and needs of people with rare diseases and caregivers of people with rare diseases in relation to accessing health services. The interview questions will be based on an extensive literature review. Data from the interviews will be analyzed using thematic analysis to identify patterns and build a thematic map. Data will be analyzed by at least 2 coders. To ensure reliability, respondent validation will be conducted and negative cases investigated. Any discrepancies will be resolved by consulting the entire research team until a consensus is reached.
RESULTS: This study was not specifically funded. However, author TČ is supported by grant number P3-0339 from the Slovenian Agency for Research and Innovation. This study was approved by the Medical Ethics Committee of the Republic of Slovenia (0120-47/2022/3), and recruitment is expected to begin in May 2024, with data analysis results anticipated by the end of 2025.
CONCLUSIONS: This study will fill an important research gap in Slovenia by exploring the needs and experiences of people living with rare diseases and their caregivers. The results will contribute to the broader field of rare diseases and add knowledge that can inform future research processes and intervention strategies. It also aims to identify neglected areas that have a significant impact on the lives of people with rare diseases. This study is important not only because it addresses the immediate needs of the Slovenian rare disease community, but also because it contributes to a discussion on patient-centered care, health policy design, and the inclusion of psychosocial components in health care.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): PRR1-10.2196/53362.
Therapeutic compsn. for re-establishing the defence mechanisms, specific and general, in man and animals, comprising as active ingredient a protein fraction M, a euglobulin, obtained by dilution of serum or other fluids with water, isolating fraction B (immunising fraction) and further diluting the supernatant with 3 vols. of water to give a precipitate of fraction M. Used parenterally, 2 mg/ml. ampoules. Useful in treatment of migraine, upper respiratory infections, mongolism, retarded children, neuroses, allergies, rheumatism, vocal diorders, sinusitis, mononucleosis, postraumatic brain syndrome, repealed angina. Fraction M has been known but, not used, in therapy before as it was said to be a sensitising fraction. Fractions M and B may be used in conjunction if desired.
A single ultrasound-guided intraarticular injection of 0.50 ml of 40 mg/ml triamcinolone acetonide at baseline. A smaller dosage can be considered if there is increased resistance during injection. The same injection procedure will be repeated after 12 weeks if there is pain (NRS≥3) and inflammation (grey scale synovitis grade 1-3) present in the CMC-1 joint.
Interleukin-1 is a prototypic proinflammatory cytokine that is elevated in cytokine storm syndromes (CSSs), such as secondary hemophagocytic lymphohistiocytosis (sHLH) and macrophage activation syndrome (MAS). IL-1 has many pleotropic and redundant roles in both innate and adaptive immune responses. Blockade of IL-1 with recombinant human interleukin-1 receptor antagonist has shown efficacy in treating CSS. Recently, an IL-1 family member, IL-18, has been demonstrated to be contributory to CSS in autoinflammatory conditions, such as in inflammasomopathies (e.g., NLRC4 mutations). Anecdotally, recombinant IL-18 binding protein can be of benefit in treating IL-18-driven CSS. Lastly, another IL-1 family member, IL-33, has been postulated to contribute to CSS in an animal model of disease. Targeting of IL-1 and related cytokines holds promise in treating a variety of CSS.
The screenings for the next 2 decades indicate an exponential increase in the incidence of neoplastic diseases in the elderly population. In order to successfully balance effectiveness and low toxicity of immunochemotherapy, a treatment personalisation based on an objective evaluation of fitness is therefore needed. The use of geriatric screening is a first step to rationalize decisions in this regard, the G8 tool has demonstrated the ability to identify patients and mostly to objectively separate elderly fragile patients from those who are fit. In that consideration, the individualization of the anticancer treatment based on a Comprehensive Geriatric Assessment (CGA) is desirable in elderly fragile patients with solid or haematological malignancy. Cancer mortality is constantly increasing after 65 years and the consequent increase in life expectancy favour the processes of cellular senescence. In this context G8 fragility assessment will take place in the screening test and by using the EORTC QLQ-C30C questionnaire to assess quality of life (QoL). The evaluation of senescent cells will be done by real-time PCR. Our aims are i) to evaluate the impact of the CGA on the QoL of elderly onco-haematological patients, candidates for complex therapies, that resulted as fragile at the G8 geriatric screening and ii) to evaluate the senescent cells in the peripheral blood of the patients enrolled in the study. The study is expected to contribute to precision medicine management of elderly patients and refine the therapeutic stratifications.
The study will be a four-center, randomized, dose finding trial to evaluate safety, preliminary efficacy, and immunogenicity of Aventis Pasteur smallpox vaccine (APSV) in healthy, vaccinia-naive adults. Four concentrations of APSV, derived from 2 lots of vaccine, will be tested; ranging from 10 (exponent 6 pfu per ml) to 10 (exponent 7.5 pfu per ml). Four concentrations of Dryvax (ranging from 10 exp 6 per ml to 10 exp 8 per ml) will be evaluated as a positive control. This study is designed to assess the feasibility of the use of APSV and dilutions of APSV in an emergency vaccination scenario. The study will be conducted in two phases. The initial phase will consist of a single-center, randomized, open-label study in 45 subjects to evaluate the safety and approximate the take rate of undiluted APSV (two lots APSV plus a Dryvax control arm: n=15 per arm). A 14 day post vaccination safety follow-up will be completed for all subjects vaccinated in the initial phase prior to initiation of the second phase of the study with an additional 285 subjects. All subjects will be followed for 56 days post vaccination with a clinic visit at day 180 for stage 1 subjects and a follow-up phone call at day 180 for stage 2 subjects. The expansion phase of the study will be conducted at three additional sites.
FIELD: medicine. SUBSTANCE: method deals with treating myasthenia, particularly myasthenic crisis, in case of relapses after thymectomy. The method includes medicinal therapy with anticholinesterase and hormonal preparations. It is suggested to inject additionally by drops an antilympholin KP preparation at 3-4 mg/kg body weight once daily in a day for the course of 2-4 d. This enables to restore nervous-muscular conductivity, decrease the content of immune-competent lymphocytes and prolong remission of the disease. EFFECT: higher efficiency of therapy. 3 ex
PURPOSE:To obtain the titled imparter providing a liquid cosmetic such as shampoo, rinse, etc., with pearly luster with a small amount and in a wide pH range, not damaging foaming properties, having high-temperature stability, by adding an aqueous solution of protein to hydrogenated lecithin. CONSTITUTION:Water-soluble protein is added to hydrogenated lecithin having 0-40 iodine value. Further the prepared suspension has high stability when the prepared suspension is subjected to Ca<2+> fusion method wherein the suspension is agglomerated with Ca<2+> and the Ca<2+> is removed with a chelating agent. In the operation,when an organic alkali agent such as triethanolamine, L- arginine, etc., is used for pH adjustment, the pH range to cause the pearly luster is widened. A liquid cosmetic such as rinse, etc., is blended with 0.001-10wt%, preferably 0.05-0.20wt% of the pearly luster imparter and then is preferably adjusted to proper pH with the alkali agent. The imparter may be used alone or mixed with a synthetic pearly luster imparter such as fatty acid, etc., as another component.
Telemedicine approaches have proved to be valuable solutions for the delivery of treatment for many health-related issues, and crucial during the pandemics. Nonetheless, the efficacy of such Web-based practices in developmental dyslexia needs to be thoroughly evaluated. To this aim, the effects of a multi-componential program for neuropsychological intervention in dyslexia delivered as an outpatient program were compared with those obtained with a remotely delivered, Web-based treatment, based on the same methodological principles and delivered with the same duration and intensity. The treatment-related changes obtained with a combination of visual hemisphere-specific stimulation and training of visual-spatial attention through action video games, were compared to those obtained through remote treatment via the Tachidino Web-based platform. Both treatments had a duration of 4 weeks. The same battery of reading and phonemic awareness tests was delivered in presence, before and after treatment, as well as at 6-months follow-up. User satisfaction was assessed through parents and user questionnaires. Both treatments were significantly and similarly effective in improving reading speed, reading accuracy, and writing accuracy. No reduction in the effects was observed after treatment discontinuation. The Web-based treatment may thus offer a valid alternative to in-person intervention, optimizing the flexibility, capillary diffusion and cost-effectiveness of intervention.
Current communication deals with the flow impact of blood inside cosine shape stenotic artery. The under consideration blood flow is treated as Newtonian fluid and flow is assumed to be two dimensional. The governing equation are modelled and solved by adopting similarity transformation under the stenosis assumptions. The important quantities like Prandtl number, flow parameter, blood flow rate and skin friction are attained to analyze the blood flow phenomena in stenosis. The variations of different parameters have been shown graphically. It is of interest to note that velocity increases due to change in flow parameter gamma and temperature of blood decreases by increasing nanoparticles volume fraction and Prandtl number. In the area of medicine, the most interesting nanotechnology approach is the nanoparticles applications in chemotherapy. This study provides further motivation to include more convincing consequences in the present model to represent the blood rheology.
The standard treatment for decompensated cirrhosis is liver transplantation, however, it has several limitations, including small donor pool, long waiting list, and several complications. Recent animal studies suggest that bone marrow stem cell transplantation can lead to regression of liver fibrosis. The investigators have already completed the phase 1 study of bone marrow mesenchymal stem cell (MSC) transplantation in 4 patients with cirrhosis. The procedure was safe, and feasible, and led to somewhat promising results (Mohamadnejad M, et al. 2006; Submitted for publication). The aim of this study is to find efficacy of this new treatment strategy in the setting of a multicenter, randomized placebo controlled trial. After assignment of the written informed consent, thirty six patients with decompensated cirrhosis will be enrolled, and will be randomized by block randomization into treatment or placebo arm. All the enrolled patients will be in the waiting list of liver transplantation. In the treatment arm bone marrow of the patients will be aspirated, and autologous bone marrow mesenchymal stem cells will be cultured, and then will be infused through a peripheral vein. Also, the corresponding placebo will be infused for the placebo group. The patients will be followed up for 1 year after performing the procedure.
PROBLEM TO BE SOLVED: To obtain a new compound, a glycosyl group-bearing specific active compound, high in stability and slight in side effects, and useful as a prodrug for preventing/treating tumors, autoimmune diseases and chronic inflammatory diseases such as chronic arthrorheumatism. SOLUTION: This new compound is shown by formula I [glycosyl is derived from a polysaccharide, oligosaccharide or monosaccharide each subject to scission by an enzyme; W is a 5- to 14-membered aromatic group, 5- to 14-membered heterocyclic group, 1-6C alkyl, 2-6C alkenyl, etc.; R is H, a 1-4C alkyl, phenyl, CN, OH, NO2 , halogen, etc.; X is O, NH, methyleneoxy, etc.; Y is O or NH; Z is a 1-4C alkylamino, N(CH3 ) or NH; (p) is 0 or 1; (n) is 0 or 1-3] and useful as a preventive/therapeutic agent for cancerous diseases, autoimmune diseases, chronic inflammatory diseases, etc. This compound is obtained by reaction of a compound of formula II with an active compound bearing activated carboxyl, amino or imino group in the presence of a solvent such as acetonitrile followed by eliminating the protecting group.